Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis – New England Journal of Medicine (link to abstract – $ for full-text)   Commentary on Twitter In a placebo-controlled trial, treatment with the phosphodiesterase 4 inhibitor BI 1015550 prevented a decrease in lung function over a 12-week period in patients with idiopathic pulmonary […]

The post Trial of a preferential Phosphodiesterase 4B Inhibitor for idiopathic pulmonary fibrosis. appeared first on Links Medicus.